Skip to content
  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
  • English
  • French
PHP Toggle Menu

Category: Press release

Positive data on key clinical candidates delivered in 2022 – Promising outlook for 2023 as industry interest in therapeutic cancer vaccines and oncolytic viruses gains significant momentum

2022 full-year results and business update 15

Published 16 March 2023
Categorized as 2023, dates, dates, Press release

Transgene to Present Multiple Posters Highlighting the Potential of its Exciting Immunotherapy Pipeline at AACR 2023

Transgene to present multiple posters highlighting the potential of its exciting immunotherapy pipeline at AACR2023 15

Published 15 March 2023
Categorized as 2023, dates, Press release, TG4001, TG4050, TG6002, TG6050-en

Transgene Appoints John C. Bell and Pedro Romero as Key Scientific Advisors

Transgene appoints John C Bell and Pedro Romero as Key Scientific advisors 15

Published 9 March 2023
Categorized as 2023, dates, dates, Press release

Transgene Receives Approval to Start a Phase I Trial of TG6050, a Novel IL-12-Armed Oncolytic Virus Given by Intravenous Administration

Transgene recieves approval to start a Phase I trial of TG6050 15

Published 6 January 2023
Categorized as 2023, categorie-orpheline, dates, Invir.IO, Press release, TG6050-en

Transgene announces Financial Calendar for 2023

Transgene announces Financial Calendar for 2023 15

Published 4 January 2023
Categorized as 2023, dates, Invir.IO, Press release, TG6002

Transgene Announces Upcoming Investor Meetings

Transgene announces upcoming investor meetings

Published 15 December 2022
Categorized as 2022, Press release

Transgene and BioInvent joint paper on BT-001 wins JITC “Best Oncolytic and Local Immunotherapy Paper” Award for 2022

Transgene and BioInvent joint paper on BT-001 wins JITC “Best Oncolytic and Local Immunotherapy Paper” Award for 2022

Published 14 November 2022
Categorized as 2022, BT-001, dates, Press release

Transgene reports business update and Q3 2022 financial position

TRANSGENE reports business update and Q3 2022 financial position

Published 7 November 2022
Categorized as 2022, 2022, Press release, dates, dates, Invir.IO, Press release

Transgene Announces Positive Interim Analysis Results of Phase II Trial Evaluating TG4001 + Avelumab vs Avelumab in HPV-Positive Anogenital Cancers

TRANSGENE announces positive interim analysis results of Phase II trial evaluating TG4001

Published 2 November 2022
Categorized as 2022, 2022, Press release, dates, Invir.IO, Press release, TG4001, TG4001

R&D Day: Presentations to Highlight Transgene’s Competitive Positioning, Capabilities to Engineer Novel Immunotherapies for Patients with Cancer, and Update on Initial Clinical Data

TRANSGENE R&D DAY

Published 27 September 2022
Categorized as 2022, Invir.IO, Press release, TG4001, TG4001, TG4050, TG6002

Posts pagination

Newer posts Page 1 … Page 11 … Page 33 Older posts
Get to know us

About us

myvac

Pipeline

Investors

Partnering

Company

Career

ESG

Suppliers

Contacts

Legal documents

Legal notices

Privacy Policy

Ethics and compliance

Cookie policy

  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
  • English
  • French
Menu